Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor

被引：0
|
作者：
Chen, H. [1 ]
Wang, W. [2 ]
Li, X. [1 ]
Xu, C. [3 ]
Zhu, Y. [1 ]
Du, K. [1 ]
Fang, M. [2 ]
机构：
[1] Zhejiang Rongjun Hosp, Jiaxing, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Fujian Canc Hosp, Fuzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Hepatoid adenocarcinoma; EGFR mutation; tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.02
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [41] Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
    Tanaka, Midori
    Ishii, Hidenobu
    Moribuchi, Hayato
    Naito, Yoshiko
    Matsuo, Norikazu
    Nakamura, Masayuki
    Tokito, Takaaki
    Azuma, Koichi
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 715 - 717
  • [42] Qualification for the treatment of Tyrosine Kinase inhibitors in a patient with adenocarcinoma of the lung with the presence of activating mutation in the EGFR gene Comment
    Kowalski, Dariusz M.
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G17 - G17
  • [43] Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
    Midori Tanaka
    Hidenobu Ishii
    Hayato Moribuchi
    Yoshiko Naito
    Norikazu Matsuo
    Masayuki Nakamura
    Takaaki Tokito
    Koichi Azuma
    Kazuhiko Yamada
    Tomoaki Hoshino
    Investigational New Drugs, 2018, 36 : 715 - 717
  • [44] Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
    Luo, Jia
    Makhnin, Alex
    Tobi, Yosef
    Ahn, Linda
    Hayes, Sara A.
    Iqbal, Afsheen
    Ng, Kenneth
    Arcila, Maria E.
    Riely, Gregory J.
    Kris, Mark G.
    Yu, Helena A.
    JCO PRECISION ONCOLOGY, 2021, 5 : 55 - 64
  • [45] Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR - Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma
    Venugopalan, Abhilash
    Khoa Nguyen
    Lynberg, Matthew
    Maity, Tapan
    Qi, Yue
    Roper, Nitin
    Cultraro, Constance
    Chan, King
    Misra, Vikram
    Thorkell, Andresson
    Zhang, Xu
    Crooks, Daniel
    Linehan, W.
    Lane, Andrew
    Guha, Udayan
    FASEB JOURNAL, 2020, 34
  • [46] Proteomics predicts chemosensitivity to EGFR tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) of lung adenocarcinoma
    Okano, T.
    Kondo, T.
    Fujii, K.
    Nishimura, T.
    Gemma, A.
    Kudoh, S.
    Hirohashi, S.
    MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (08) : S123 - S123
  • [47] Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response
    Park, Ha Young
    Oh, Hyung Joo
    Kim, Ki-Hyun
    Kim, Tae-Ok
    Park, Cheol-Kyu
    Shin, Hong-Jun
    Lim, Jung-Hwan
    Kwon, Yong-Soo
    Oh, In-Jae
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    Choi, Yoo-Duk
    THORACIC CANCER, 2016, 7 (06) : 639 - 647
  • [48] Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
    Nicos, Marcin
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    Chmielewska, Izabela
    Wojcik-Superczynska, Magdalena
    Reszka, Katarzyna
    Kieszko, Robert
    Gora-Florek, Anna
    Dudek, Malgorzata
    Swiniuch, Daria
    Papiewski, Wojciech
    Calka, Paulina
    Ciesielka, Marzanna
    Ramlau, Rodryg
    Milanowski, Janusz
    ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1496 - 1500
  • [49] Uncommon mutation types of Epidermal Growth Factor Receptor (EGFR) and tyrosine kinase inhibitor response in non-small cell lung carcinoma
    Wong, Maria P.
    Lee, Victor H. F.
    Yeung, Rebecca M. W.
    Tin, Vicky P. C.
    Choy, Kit Chi
    Liu, Jing
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [50] Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors
    Notsuda, H.
    Pham, N.
    Li, M.
    Liu, N.
    Raghavan, V.
    Fang, Z.
    Marshall, C.
    Moghal, N.
    Ikura, M.
    Tsao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S456 - S456
12345